Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Oh...It didn't start trading?

<< Previous

Bullboard Posts

Next >>

Comment by Moonshiner592on Nov 16, 2020 5:07pm

326 Views

Post# 31911074

RE:Oh...It didn't start trading?

losingmyshirt wrote: My goodness.. What can the matter be.
Don't tell me that Bob still hasn't figured out how to log on to the WiFi at IHop so that he can issue a press release
Soon be 6 months halted. No new website either? Go figure.

I was sure that the halt would be finished by now. Last week EEEEtalien had something on his foot and he figured, oh never mind.

Everything's been filed - it's out of their hands at this point .. and don't forget - COVID has slowed everything down .. Regarding Bob - He has much more than just waffles on his mind ...